Bayer Long Term Debt 2012-2025 | BAYRY
Bayer long term debt from 2012 to 2025. Long term debt can be defined as the sum of all long term debt fields.
- Bayer long term debt for the quarter ending September 30, 2025 was $38.235B, a 5.18% decline year-over-year.
- Bayer long term debt for 2024 was $38.412B, a 7.03% decline from 2023.
- Bayer long term debt for 2023 was $41.318B, a 16.05% increase from 2022.
- Bayer long term debt for 2022 was $35.602B, a 17.51% decline from 2021.
|
Bayer Annual Long Term Debt (Millions of US $) |
|
|---|---|
| 2024 | $38,412 |
| 2023 | $41,318 |
| 2022 | $35,602 |
| 2021 | $43,161 |
| 2020 | $37,920 |
| 2019 | $41,341 |
| 2018 | $44,538 |
| 2017 | $14,110 |
| 2016 | $17,905 |
| 2015 | $18,336 |
| 2014 | $24,571 |
| 2013 | $7,425 |
| 2012 | $8,954 |
| 2011 | $10,705 |
|
Bayer Quarterly Long Term Debt (Millions of US $) |
|
|---|---|
| 2025-09-30 | $38,235 |
| 2025-06-30 | $35,993 |
| 2025-03-31 | $36,894 |
| 2024-12-31 | $38,412 |
| 2024-09-30 | $40,325 |
| 2024-06-30 | $40,273 |
| 2024-03-31 | $41,242 |
| 2023-12-31 | $41,318 |
| 2023-09-30 | $38,215 |
| 2023-06-30 | $39,862 |
| 2023-03-31 | $36,035 |
| 2022-12-31 | $35,602 |
| 2022-09-30 | $39,744 |
| 2022-06-30 | $40,505 |
| 2022-03-31 | $41,126 |
| 2021-12-31 | $43,161 |
| 2021-09-30 | $43,600 |
| 2021-06-30 | $44,176 |
| 2021-03-31 | $45,714 |
| 2020-12-31 | $37,920 |
| 2020-09-30 | $41,137 |
| 2020-06-30 | $37,379 |
| 2020-03-31 | $40,611 |
| 2019-12-31 | $41,341 |
| 2019-09-30 | $41,991 |
| 2019-06-30 | $41,277 |
| 2019-03-31 | $43,105 |
| 2018-12-31 | $44,538 |
| 2018-09-30 | $46,924 |
| 2018-06-30 | $50,796 |
| 2018-03-31 | $15,086 |
| 2017-12-31 | $14,110 |
| 2017-09-30 | $19,410 |
| 2017-06-30 | $15,583 |
| 2017-03-31 | $18,244 |
| 2016-12-31 | $17,905 |
| 2016-09-30 | $18,431 |
| 2016-06-30 | $18,625 |
| 2016-03-31 | $18,886 |
| 2015-12-31 | $18,336 |
| 2015-09-30 | $18,625 |
| 2015-06-30 | $19,002 |
| 2015-03-31 | $19,099 |
| 2014-12-31 | $24,571 |
| 2014-09-30 | $15,129 |
| 2014-06-30 | $10,985 |
| 2014-03-31 | $11,104 |
| 2013-12-31 | $7,425 |
| 2013-09-30 | $7,685 |
| 2013-06-30 | $9,541 |
| 2013-03-31 | $9,030 |
| 2012-12-31 | $8,954 |
| 2012-09-30 | $8,906 |
| 2012-06-30 | $9,407 |
| 2012-03-31 | $10,390 |
| 2011-12-31 | $10,705 |
| 2011-09-30 | $10,649 |
| 2011-06-30 | $10,433 |
| 2011-03-31 | $13,039 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $53.369B | $50.438B |
| Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $981.092B | 42.96 |
| Johnson & Johnson (JNJ) | United States | $586.690B | 22.54 |
| AbbVie (ABBV) | United States | $409.150B | 23.15 |
| Roche Holding AG (RHHBY) | Switzerland | $372.740B | 0.00 |
| Novartis AG (NVS) | Switzerland | $344.536B | 18.16 |
| Merck (MRK) | United States | $301.342B | 13.53 |
| Novo Nordisk (NVO) | Denmark | $221.330B | 12.68 |
| Pfizer (PFE) | United States | $156.812B | 8.54 |
| Sanofi (SNY) | France | $112.219B | 10.39 |
| Innoviva (INVA) | United States | $1.697B | 8.50 |